Oral iron therapy for children with chronic kidney disease
Official title: Pilot Pragmatic Clinical Trial of Oral Iron Therapy in Children With Chronic Kidney Disease
Run by Weill Medical College of Cornell University · NCT03991169 · Data updated 2026-11-12
This study is testing if giving oral iron supplements to children with chronic kidney disease and mild anemia can help improve their strength, activity levels, and eating habits.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 1 Year to 21 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Weill Medical College of Cornell University Academic / other |
| Locations | 2 sites (New York, New York and 1 other locations) |
| Status | Recruiting |
| Started | April 19, 2019 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | August 11, 2025 |
| Trial ID | NCT03991169 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children aged 1-21 years with chronic kidney disease and mild anemia, specifically those with certain hemoglobin and transferrin saturation levels.
✕Probably not a fit
Patients who have severe iron deficiency or are currently receiving iron therapy or erythropoietin will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot clinical trial investigates the effects of oral iron therapy using ferrous sulfate in children aged 1-21 years with chronic kidney disease (CKD) and mild anemia. Participants will be randomly assigned to receive either standard iron sulfate treatment or no iron therapy for a duration of three months. The study aims to evaluate outcomes such as muscle strength, physical activity, and changes in eating behavior, measured at the start and end of the trial. The goal is to determine the efficacy of oral iron in improving health metrics in this vulnerable population.
Why it matters
Potential benefit: If successful, this study could improve the management of anemia in children with chronic kidney disease, enhancing their overall health and quality of life.
How similar studies have gone: Other studies have explored iron therapy in similar populations, showing promising results, but this specific approach is still being evaluated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Key inclusion criteria: * Age 1-21 years old (muscle strength will be assessed only in children \>3 year old) * Estimated glomerular filtration rate (GFR) \< 90 ml/min/1.73m2 by bedside Schwartz formula \[height (cm) \*0.413 / serum creatinine (mg/dL)\] * Hemoglobin (Hb) more or equal than 9.0 at the previous clinic visit * Hb less than 11.5 g/dL in children younger than 5 years Hb less than 12.0 g/dL in children 5-12 years Hb \<12.5 g/dL in children 12-15 yrs and females \>15 yrs. Hb \<13.5 g/dL in males \>15 years (all at the previous clinic visit) Children with transferrin saturation ≤ 20% AND serum ferritin ≤ 100 ng/mL will be randomized into one of the arms Key exclusion criteria: * Transferrin saturation \<5% * Serum ferritin \< 10 ng/mL * Iron therapy or erythrocyte stimulating agents (erythropoietin) therapy within 3 months prior to randomization * Blood transfusion within 4 months prior to enrollment * Children on hemodialysis * Rapidly deteriorating kidney function or expectation for transplantation or dialysis in less than 3 months * Pregnancy and breast-feeding
Where it's running
-
Weill Cornell Medicine / New York Presbyterian Hospital
New York, New York, United States Recruiting -
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Oleh Akchurin, M.D. — Weill Cornell College of Medicine
- Study coordinator: Akeem Noziere, B.S.
- Email: akn4001@med.cornell.edu
- Phone: 646-962-8313
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Project to improve understanding and treatment of kidney diseases
This study is trying to find better ways to understand and treat kidney diseases by looking closely at kidney samples and patient data to help create personalized care plans.
-
Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes
This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.
-
Impact of TAVR on kidney function in people with aortic valve disease
This registry tests how trans-catheter aortic valve implantation affects kidney function and the risk of kidney injury in adults with aortic stenosis.
-
Calciphylaxis in people with chronic kidney disease: causes, risks, and early signs
This project will compare adults with chronic kidney disease who develop calciphylaxis to matched CKD patients who do not, collecting clinical data and biological samples to try to find risk factors and early signs.
-
Oral Semaglutide for CKD and MAFLD in adults with diabetes
This study tests whether adding oral semaglutide to standard care can slow kidney and liver disease progression in adults with CKD and MAFLD who have type 2 diabetes.
-
Eye-brain-kidney connections in chronic kidney disease
This study will see if changes in brain network connectivity and retinal blood vessels are linked to cognitive decline and kidney function in adults with chronic kidney disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.